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Abstract
Background: Mutation in the ubiquitously expressed cytoplasmic superoxide dismutase (SOD1) causes an inherited form of
Amyotrophic Lateral Sclerosis (ALS). Mutant synthesis in motor neurons drives disease onset and early disease progression.
Previous experimental studies have shown that spinal grafting of human fetal spinal neural stem cells (hNSCs) into the
lumbar spinal cord of SOD1G93A rats leads to a moderate therapeutical effect as evidenced by local a-motoneuron sparing
and extension of lifespan. The aim of the present study was to analyze the degree of therapeutical effect of hNSCs once
grafted into the lumbar spinal ventral horn in presymptomatic immunosuppressed SOD1G93A rats and to assess the
presence and functional integrity of the descending motor system in symptomatic SOD1G93A animals.
Methods/Principal Findings: Presymptomatic SOD1G93A rats (60–65 days old) received spinal lumbar injections of hNSCs.
After cell grafting, disease onset, disease progression and lifespan were analyzed. In separate symptomatic SOD1G93A rats,
the presence and functional conductivity of descending motor tracts (corticospinal and rubrospinal) was analyzed by spinal
surface recording electrodes after electrical stimulation of the motor cortex. Silver impregnation of lumbar spinal cord
sections and descending motor axon counting in plastic spinal cord sections were used to validate morphologically the
integrity of descending motor tracts. Grafting of hNSCs into the lumbar spinal cord of SOD1G93A rats protected a-
motoneurons in the vicinity of grafted cells, provided transient functional improvement, but offered no protection to a-
motoneuron pools distant from grafted lumbar segments. Analysis of motor-evoked potentials recorded from the thoracic
spinal cord of symptomatic SOD1G93A rats showed a near complete loss of descending motor tract conduction,
corresponding to a significant (50–65%) loss of large caliber descending motor axons.
Conclusions/Significance: These data demonstrate that in order to achieve a more clinically-adequate treatment, cell-
replacement/gene therapy strategies will likely require both spinal and supraspinal targets.
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Introduction
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s
disease, is characterized by the progressive development of motor
dysfunction, a-motoneuron degeneration and death, in turn
producing progressive fatal paralysis. Both inherited and sporadic
instances of disease combine lower a-motoneuron degeneration
and upper motor neuron lesion(s) [1,2]. Depending on the time
course of a-motoneuron degeneration within spinal cord segments
(cervical, lumbar or both), the early clinical manifestation of
disease typically presents as motor weakness with progressive loss
of ambulatory and/or respiratory function. In addition to motor
deficits, several other qualitatively distinct neurological symptoms
including muscle spasticity and segmental hyper-reflexia are also
frequently seen during disease progression [1].
While the pathological mechanisms leading to progressive
neuronal degeneration are likely multi-factorial, there is converg-
ing evidence for the role of both motor neurons and astrocytes as
key disease mediators. Early studies identified functional abnor-
malities in astroglial-specific glutamate transporters (EAAT2) in
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both sporadic and familial ALS human tissues [3], as well as
mutant SOD1 transgenic rodent models [4,5]Howlan}. The role
of non-motor neurons in the evolution of a-motoneuron degen-
eration in ALS was initially validated by analysis of chimeric
mouse models that were mixtures of normal and mutant SOD1
expressing cells. Those studies revealed that normal motor neurons
within an ALS-causing mutant cell environment develop disease-
related damage [6]. In addition, analysis of other chimeric mice in
which 100% of motor neurons expressed high levels of a disease-
causing ALS mutation in SOD1 demonstrated that the presence of
normal non-neuronal cells could delay or eliminate disease [7].
Diminished mutant SOD1 synthesis from astrocytes strongly
slowed the rate of disease progression [7]. Finally, in vitro studies
have provided evidence that ALS glia isolated from mutant SOD1
transgenic mice release factors (not yet identified) that are
sufficient to trigger human and rodent motor neuron degeneration
in vitro [8–11]. Thus, the loss of astrocyte–mediated glutamate
buffering capacity and the secretion of toxic factors from local
astrocytes may both contribute to neuronal degeneration in ALS.
Consistent with these mechanism-exploratory studies, which
identified the role of mutated astrocytes in disease progression,
recent in vivo spinal cell grafting data provided evidence that local
segmental enrichment with wild-type neural or astrocyte precur-
sors leads to a certain degree of neuroprotection. Focal enrichment
of normal astrocytes, by transplantation of fetal rat spinal cord-
derived, lineage-restricted astrocyte precursors (AP), produced
significant benefit in a rat model that develops fatal motor neuron
disease from expression of mutant SOD1G93A. AP transplantation
adjacent to cervical spinal cord respiratory motor neuron pools,
the principal cells whose dysfunction leads to death in ALS,
survived in diseased tissue, differentiated efficiently into astrocytes
and reduced microgliosis in the cervical spinal cords of SOD1G93A
rats. Functionally, AP-grafted animals showed: i) extended survival
and disease duration, ii) attenuated motor neuron loss, iii) slowed
declines in forelimb motor performance, and iv) improved
respiratory functions. It was hypothesized that neuroprotection
was mediated in part by the primary astrocyte glutamate
transporter EAAT2 expressed in grafted cells (called GLT1 in
rodents) [12].
Mutant damage within motor neurons has also been demon-
strated to play a central role in development of disease. In rodent
models, diminishing mutant SOD1 synthesis within motor
neurons (by selective transgene inactivation [7,13] or viral-
mediated siRNA delivered by retrograde transport after intra-
muscular injection [14,15] can sharply delay disease onset. Spinal
lumbar grafting of human fetal spinal neural stem cells (i.e., the
same cells as used in our current study) in immunosuppressed
SOD1G93A rats has been reported to yield long-term graft survival
(average 86 days) and formation of synapses with the host neurons.
Grafted animals were reported to have disease onset delayed by 7
days and the age at which limb paralysis was reached was
extended by 11 days [16,17].
The compelling evidence of non-cell autonomous contributions
to disease in models of SOD1 mediated ALS makes cell
replacement therapy an attractive option. We now report the
long term survival and differentiation into neurons and astrocytes
of human fetal spinal neural stem cells (hNSCs) after grafting into
the vicinity of lumbar spinal a-motoneurons and a local transient
functional benefit after grafting into immunosuppressed presymp-
tomatic SOD1G93A rats.
Results
Grafted human fetal spinal neural stem cells (hNSCs)
show long term survival, develop neuronal
morophologies and form synapses with host a-
motoneurons
Twenty-four, SOD1G93A rats (12 male, 12 female; 60–65 days
old) received 10 bilateral injections of hNSCs targeted into ventral
horn of L2–L5 spinal segments (Fig. 1A, B). Sixteen additional
animals received media only. All animals survived until endstage
disease, with the exception of one media- and two cell-treated
animals which died perioperatively. Immunohistological examina-
tion of spinal cord tissue from animals at endstage using an antibody
recognizing the human, but not rat, nuclear matrix protein
(hNUMA) revealed identifiable human grafts in 18/22 animals.
Four animals were graft-negative as indicated by injection tracks
which were clearly visible, but with no human antigen detected (data
not shown). hNUMA-immunoreactive cell grafts were found in the
central and deep gray matter (laminae VII–IX) and sometimes
extended into white matter (Fig. 1C). The overall appearance of
spinal cords from cell-grafted animals was generally unremarkable,
with only some examples of cell grafts extended into the white matter
and slight enlargement of the spinal cord was then sometimes noted
typically in the area closest to the graft. The pattern of engraftment
identified by antibodies selective for human neuron-specific enolase
(hNSE) (Fig. 1D) or doublecortin (DCX; Fig. 1E), an early
postmitotic neuronal marker, closely matched that seen with
hNUMA. Essentially all structures within the graft core labeled for
both hNSE and doublecortin (Fig. 1F). Numerous individual
doublecortin/hNUMA-immunopositive cells were readily found
outside the graft core and had long neural-like processes with axonal
varicosities (often more than 500 mm in length; Fig. 1G).
Quantitative analyses showed that 7866% of hNUMA-positive
nuclei were surrounded by a doublecortin-positive cytoskeleton,
suggesting that those cells were young, migrating, post-mitotic
neurons. Likewise, no cells with doublecortin were found lacking
an hNUMA-positive nucleus. Similar to the hNSE staining
pattern, fibers with doublecortin were found extending
.500 mm radially from the graft core, sometimes crossing
through/near lamina X to the opposite side. On average
12.561.2% of hNUMA-positive cells expressed the mature
neuron marker NeuN (Fig. 1H). Graft cores identified with
hNUMA were also intensely stained for the neuron-specific
cytoskeletal protein bIII tubulin (TUJ1; [18]; Fig. S1A–C) and
GAP43 (Fig. S1D–G). Only 1.761.1% of hNUMA-positive cells
appeared to be astrocytes with detectable GFAP filaments
(Fig. 1I). Only 3.260.9% of hNUMA-positive cells reacted with
the mature oligodendrocyte marker APC (not shown).
Examination of grafted spinal cord tissue revealed a dense fiber-
like pattern of human-specific synaptophysin within the core and
extending outward into the adjacent tissue (Fig. 1J, Fig. S2A–D).
Persisting host motoneurons (a and c) were frequently found to
have human-specific synaptophysin-positive bouton-like structures
adjacent to their cell body and associated processes. By examining
specific neurotransmitter phenotype markers in 0.5 mm-thick
optical sections, 0.860.3% of human synaptophysin-positive
structures were co-labeled with glutamate decarboxylase 65
(GAD65; Fig. 1K; Fig. S2E–H), a marker for c-aminobutyric
acid-producing neurons. Immunostaining for each of the three
vesicular glutamate transporters known to exist in the spinal cord
(VGluT 1, 2, and 3) revealed that 1.360.5% of boutons with
human synaptophysin were glutamatergic (Fig. 1L; Fig. S2I–L).
Glycinergic boutons, identified by immunostaining for a glycine
transporter (GlyT2) represented 0.960.6% of these boutons (Fig.
Cell Replacement Therapy for ALS
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Figure 1. Human spinal neural stem cells grafted into lumbar spinal cord of SOD1G93A rats show long term survival and preferential
neuronal differentiation. Using a glass capillary SOD1G93A rats (60–65 days old) received 10 bilateral injections of hNSCs targeted into the
intermediate zone (lamina VII) and ventral horn (lamina VIII, IX) of L2–L5 spinal segments (A, B). Lumbar spinal cord sections from cell-grafted
SOD1G93A animals immunostained for human nuclear matrix antigen (hNUMA) to identify all cells of human origin and developed by
diaminobenzidine (C) shows a dense population of nucleus-like structures throughout the mid- and deep laminae (dashed line delineates the ventral
horn) as well as more disperse nuclei outside the graft core and often into the white matter (inset). Neighboring sections revealed cell grafts that
were strongly immunoreactive (IR) for human neuron-specific enolase (hNSE) and doublecortin (DCX; D–G). Other hNUMA-IR cells were found to react
with the neuronal nuclear protein NeuN (H) and glial fibrillary acidic protein (GFAP; I). Human synaptophysin (hSYN) was detected throughout the cell
grafts and was often found in the vicinity of persisting motoneurons (ChAT; choline acetyltranseferase) in lamina IX and extending into the adjacent
white matter (J). Single optical layer confocal images of surviving a -motoneurons show hSYN-IR bouton-like structures adjacent to the outer
membrane of the soma (K, L). Only occasional hSYN-IR boutons co-stained with the GABA-ergic cell marker glutamate decarboxylase (GAD65; K);
glutamatergic boutons were located by identifying specific glutamate vesicular transporters 1/2/3 (VGluT) and similarly showed only rare boutons
also reactive for hSYN (L). Arrows show some examples of double-immunoreactive structures. Scale bar: 300 mm (C, F), 700 mm (D, E), 35 mm (G),
10 mm (H, I), 250 mm (J), 20 mm (K, L).
doi:10.1371/journal.pone.0042614.g001
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S2M–P), consistent with a human stem cell-derived glycinergic
neuron. No synaptophysin-positive structures were found to co-
label with the motor neuron marker ChAT (Fig. 1K, L; Fig.
S2H, L, P). Indeed, in the vast majority (.97%) of cases human
synaptophysin-positive cells did not contain any differentiated cell
marker, indicating a persistent immature phenotype.
Human spinal neural stem cells protect a-motoneurons
in grafted segments
In order to assess a possible protective effect of grafted hNSCs
on lumbar a-motorneuron survival we performed quantitative
histological analyses of persisting lamina IX a-motoneurons in
normal, SOD1G93A, SOD1G93A/hNSCs-grafted, and SOD1G93A/
media-treated animals in the lumbar (L4–L5) spinal cord
segments. Representative half spinal cord images from each
animal group are shown in Fig. 2A–D. In untreated SOD1G93A
animals, there was an average 8567% reduction in the number of
a-motoneurons per histological section compared to untreated,
non-transgenic rats (Fig. 2I). While media-treated SOD1G93A rats
showed an 8069% reduction in the a-motoneuron population, in
hNSCs-grafted animals the lateral a-motorneuron pool showed
only a 5365% decrease relative to normal animals), which was a
significantly smaller reduction than the untreated or media-treated
SOD1G93A animal groups (P,0.001; one-way ANOVA).
Analysis of a-motoneuron survival in the phrenic nucleus (C5–
6) was used to test whether the lumbar cell grafts provided
protection in cervical motoneuron pools distant from grafted
lumbar segments. Half spinal cord images from untreated normal
animals showed an intensely-stained (choline acetyl transferase -
ChAT) motoneuron pool in cervical spinal cord (Fig. 2E).
Untreated SOD1G93A animals at endstage disease developed a
dramatic loss in the a-motoneuron population (Fig. 2F, J; a
6964% reduction compared to age-matched non-transgenic
littermates). Media-treated (Fig. 2G) and hNSCs-grafted
(Fig. 2H) SOD1G93A animals had similarly-reduced cervical
motor pools (6064% and 6564% of normal littermates,
respectively).
Grafted human spinal neural stem cells ameliorate
lumbar astrogliosis and microglial activation
To test how engraftment of hNSCs affects the astroglial and
microglial activation that prominently develop in SOD1G93A rats,
region-specific (lamina IX) astrogliosis and microglial activation
was assessed by densitometric analysis of glial fibrillary acidic
protein (GFAP) and ionized calcium-binding adaptor molecule 1
(Iba1) immunoreactivity, respectively. Untreated normal rats
showed minimal GFAP reactivity as expected for wild-type
animals, with very thin processes in astrocytes and usually no
discernable cell body (Fig. S3A). Iba1 immunoreactivity was also
comparable to that of wild-type naı¨ve animals, with microglia with
long thin processes (Fig. S3B). However, by endstage disease,
intense reactive astrogliosis (i.e., hypertrophic astrocytes with
short, thick processes and enlarged soma) was found in the
untreated SOD1G93A rats (Fig. S3D, M). Microglial activation in
SOD1G93A mutant animals paralleled the reactive astrogliosis with
a significant increase in the presence of Iba1+ cells throughout the
ventral horn (and concentrated in lamina VIII and IX - Fig. S3E,
M). While media treatment did not alter development of GFAP or
Iba1 reactivity in laminae IX (compared to untreated, mutant
SOD1G93A tissue; Fig. S3I, M), hNSCs-transplantation reduced
the overall immunoreactivity for GFAP and Iba1 (Fig. S3L, M).
While media-treated tissue had GFAP and Iba1 reactivities 860.9
and 660.8 fold greater than that in normal animals, both were
reduced [to 460.8 fold (p = 0.04; one-way ANOVA) and 3.660.4
fold (p = 0.02; one-way ANOVA)] in hNSCs grafted animals,
respectively.
Grafted human spinal neural stem cells migrate
extensively and form synapses
To assess the degree of cell migration and synapse formation at
extended periods after grafting, we compared non-quantitatively
the distribution of grafted (hNUMA+) cells 9 months after
transplantation into lumbar spinal cords of immunodeficient rats
with the pattern seen in cell-grafted SOD1G93A rats (i.e., around
78 days after cell transplantation). Extensive migration of grafted
cells was seen into both white and gray mater (Fig. 3A, B; Fig.
S4A,B). Double staining of hNUMA+ sections showed that the
hNSCs-derived cells localized in white matter acquired only glial
phenotypes (Fig. 3C, D) [as shown by co-staining with antibodies
to neuronal (NeuN, human neural specific enolase - NSE, CHAT)
or non-neuronal (GFAP and the mature oligodendrocyte cell
marker APC) proteins]. hNSCs-derived cells in the gray matter, on
the other hand, had both neuronal and non-neuronal markers
(Fig. 3E). Electron microscopy confirmed that human synapto-
physin (hSYN) immunoreactive axonal terminals had formed
synapses with adjacent host neuron-derived dendrites (Fig. 3F–I).
Near complete loss of spinally-recorded motor-evoked
potentials in non-treated SOD1G93A animals
In order to assess the upper motor neuron connectivity at the
spinal level, motor-evoked potentials were recorded in a separate
group of endstage SOD1G93A rats with no previous manipulations
(i.e. no spinal media or cell injections) and age-matched non-
transgenic control animals. Motor-evoked potentials (MEPs) were
recorded from the dorsal surface of exposed thoracic T12 segment
after electrical stimulation of the motor cortex (Fig. 4A). MEPs
consist of multiple waves, with the two earliest peaks, N1 and N2,
corresponding to the activation of extrapyramidal system [19–21].
In non-transgenic animals, the N1 wave (average amplitude
140.7639.0 mV; Table 1) was recorded at 1.660.2 ms and the
N2 wave (average amplitude 88.4651.3 mV) 2.860.3 ms after the
stimulus, yielding calculated conduction velocities of 52–62 and
28–32 m/s, respectively. In SOD1G93A endstage animals, the N1
amplitude was reduced to 1/6th the normal level (25.566.4 mV,
p,0.05 compared to normal animals; t-test) and latency was
increased by 55% (to 2.560.2 ms; p,0.05; t-test) (Fig. 4 B,
Table 1). Similarly, N2 amplitude was reduced to about 30% of
normal (to 25.169.1 mV) and latency was increased 25% (to
3.560.5 ms, p,0.05; t-test) (Fig. 4B, Table 1).
Loss of large, descending myelinated axons in spinal
white matter of mutant SOD1G93A
Histological analysis of the integrity of descending motor tract
degeneration in cervical and lumbar spinal cord was determined in
terminal SOD1G93A rats which were previously used for MEPs
recording. Silver impregnation techniques were employed to
detect the presence and distribution of axo-dendritic disintegra-
tion, which is marked by silver deposition [22–25]. While lumbar
sections from the normal animals had minimal silver deposition
(Fig. 5A), similar sections from SOD1G93A animals had numerous
degenerating a-motoneurons and interneurons that stained
intensely (Fig. 5B, C) and an abundant number of fragmented
fibers coursing throughout laminae IV–X (Fig. 5D). Numerous
argyrophilic punctate structures were also prominent in most white
matter regions, particularly in the lateral and ventral columns.
Using a less sensitive silver method (de Olmos aminocupric silver
Cell Replacement Therapy for ALS
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impregnation), massive axo-dendritic degeneration (compare the
tissue from normal animals [Fig. 5E–G] with that from
SOD1G93A animals [Fig. 5H–K]) was identified in several areas
in the cervical, thoracic and lumbar spinal cord segments
including: i) the lateral and ventral white matter, ii) laminae IV–
IX within the gray matter, and iii) to a lesser degree in the dorsal
columns (Fig. 5H–K).
The total number of remaining axons and their calibers (0.5–2,
2–5, 5–14 mm in diameter) were determined in the lateral and
ventral funiculi [using semi-automated image analysis of osmium-
treated 1 mm plastic sections taken from lumbar spinal cord of
normal (n = 2; Fig. 5 L–N) and SOD1G93A (n = 2) endstage
animals with no previous manipulations (i.e. no spinal media or
cell injections; Fig. 5 O–Q)]. In normal tissue, axons of varied
caliber were clearly-outlined with myelin (Fig. 5M, N). On the
other hand, an easily recognizable reduction in the number of
large caliber myelinated axons was found in endstage tissue from
SOD1G93A animals (compare Fig. 5 M, N to P, Q). Axonal loss
in the lateral funiculus averaged 19% for 0.5–2 mm caliber axons,
40% for 2–5 mm caliber axons, and 57% of axons 5–14 mm in
diameter (Table 2). Numerous medium sized (10–15 mm) and
large (15–25 mm) vacuoles, likely evolving at sites of previous
axonal degeneration and phagocytic activity (Fig. 5 O, P, arrows),
were prominent in lumbar white matter of the SOD1G93A animals.
In addition, frequent osmium-dense deposits that were likely
macrophages and activated microglia were consistently identified
(Fig. 5O, P, arrowheads).
Transient retention in neurologic and reflex activity from
grafting of human spinal neural stem cells, but no effect
on survival of SOD1G93A animals
Development and progression of ALS-like disease in SOD1G93A
was followed after lumbar grafting of hNSCs of presmyptomatic
(60–65 days old) SOD1G93A rats (Fig. 1A). Disease onset, defined
as the peak animal body weight (Fig. 6A), in grafted animals was
not different from untreated animals (10962d, 11162, and
Figure 2. SOD1G93A rats receiving lumbar grafts of human spinal neural stem cells show higher a-motoneuron survival at the
lumbar but not cervical spinal segments. Lumbar transverse spinal cord sections from untreated, non-transgenic (Non-Tg; A) and untreated
SOD1G93A transgenic (SOD1G93A; B) animals, as well as SOD1G93A animals treated with media (SOD1G93A media; C) or human spinal neural stem cell
grafts (SOD1G93A cells, D) were double immunostained to identify all mature neurons (NeuN) and cholinergic cells (a-motoneurons, ChAT). While a
dramatic reduction in ChAT-IR cells was noted in all SOD1G93A animals, regardless of treatment, quantitative analysis (I) of persisting a-motoneurons
showed a significant increase in the a-motoneuron pool in the cell-grafted animals (D, I). Using adjacent histological sections, inset (D) shows an
example of a group of transplanted cells (positive for human nuclear matrix antigen; hNUMA) near a pool of surviving a-motoneurons. Sections taken
from the same animals but from the cervical level (C5/6) also show a dramatic reduction in the motoneuron pool but with no apparent protective
effect afforded by the lumbar cell grafts (E–H, J). Scale bar: 300 mm. * P,0.001 compared to non-transgenic, P = 0.03 compared to the media-treated
group; one-way ANOVA.
doi:10.1371/journal.pone.0042614.g002
Cell Replacement Therapy for ALS
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10863 for grafted animals, media-injected and untreated
SOD1G93A animals; p = 0.41; t-test). Grafting also produced no
statistically significant effect on progression to an early disease
point (identified by the age at which the animal had lost 10% of its
body weight from denervation-induced muscle atrophy; Fig. 6B)
between hNSCs-grafted animals and those that received media
only (12362d versus 12762d, respectively; P = 0.122; t-test).
Overall survival was also not significantly affected between the
hNSCs-grafted or media-injected animals (13663d and 14263d,
p = 0.18; t-test) (Fig. 6C). Analyzing males and females separately
failed to reveal any significant difference in any disease index (data
not shown).
On the other hand, neurological function (using a well-
established BBB scoring scale measured from each animal every
3–4 days) was significantly preserved at age 135–142d in the cell-
grafted animals compared with the media-treated group (Fig. 6D;
p,0.05; t-test). Similarly, at the same age (Fig. 6E) recording of
Hoffmann reflex revealed a higher average H-wave amplitude for
Figure 3. Effective re-population of lumbar gray and white
matter by human spinal neural stem cells nine months after
lumbar transplantation in immunodeficient rats. When human
spinal neural stem cells (same cell line as were used in the grafting
experiments in Fig. 1, 2 and Fig. S2, S3) were transplanted into the
lumbar spinal cord of immunodeficient rats, histological sections taken
after nine months of survival revealed a near homogenous distribution
of human cells (hNUMA; A, B) in both gray and white matter. In white
matter hNUMA-IR cells were primarily oligodendrocytes (adenomatous
polyposis coli; APC; C) or astrocytes (GFAP; D) while in gray matter a
neuronal phenotype (NeuN; E) was identified. Electron microscopy
revealed axon terminals, enriched with human synaptophysin immu-
noreaction product (F, G), forming synapses with host neurons or
dendrites (F, H, I). Scale bar: 300 mm (A), 100 mm (B), 30 mm (C–E),
400 nm (F), 500 nm (G), 250 nm (H, I).
doi:10.1371/journal.pone.0042614.g003
Figure 4. Motor-evoked potentials recorded from the dorsal
surface of T12 spinal cord are near completely lost in endstage
SOD1G93A rats. To identify the conductivity of descending motor
axons MEPs were elicited by electrical stimulation of motor cortex and
extra-pyramidal system and responses recorded from exposed T12
spinal segments (A). Recordings in 6 non-transgenic animals showed
consistent compound action potentials consisting of N1 and N2 waves
with an average latencies of 1.6–2.8 ms respectively (B). In contrast,
recording in 6 transgenic SOD1G93A endstage animals showed near
complete loss of N1 and N2 waves.
doi:10.1371/journal.pone.0042614.g004
Table 1. Analysis of motor-evoked potentials recorded from
the dorsal surface of the T12 spinal cord segment in non-
transgenic and endstage transgenic SDO1G93A rats.
Amplitude (mV ± SD) Latency (ms ± SD)
N1 N2 N1 N2
Non-Tg 140.7639.0 88.4651.3 1.660.2 2.860.3
SOD1G93A 25.566.4* 25.169.1* 2.560.2* 3.560.5*
The amplitudes and latencies of the N1 and N2 waves were calculated and
averaged from 6 non-tg and 6 SOD1G93A endstage animals. (* P,0.05).
doi:10.1371/journal.pone.0042614.t001
Cell Replacement Therapy for ALS
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the hNSCs-grafted group compared to the media-treated animals
(3.560.6 vs. 1.160.3 mV; p,0.05; t-test), indicating functional
preservation between sensory Ia afferent, a-motoneuron and
motor plate.
Discussion
Our results show that human fetal spinal neural stem cells
(hNSCs) grafted into the lumbar ventral horn in SOD1G93A rats
provides a region-specific neuroprotective effect in the vicinity of
the grafted cells, including a higher number of surviving a-
Figure 5. Significant degeneration of descending medium-, and large-size myelinated axons in lumbar segments in endstage
SODG93A rats. Using the Gallyas silver impregnation technique, degenerating neurons were detected mostly within the ventral horn, although
reactive cells were often noted in upper lamina (A- non-transgenic, B- SOD1G93Aendstage). Closer examination shows fragmented cells and fibers not
only within the grey matter, but also in the adjacent white matter (C, D). The de Olmos modified cupric-silver stain was used to help detect
degenerating axons and dendrites; non-transgenic tissue showed no appreciable staining (E – cervical, F-thoracic, G – lumbar), while SOD1G93A tissue
reacted intensely, not only in the ventral horns but throughout the gray matter, sparing only lamina I–III (H–J). Closer examination of the white matter
showed argyrophilic punctate structures corresponding to silver deposits in disintegrated axons (K). Semithin (1 mm) plastic-embedded tissue
sections were used to quantify changes in the axonal population in the lateral and ventral columns. While clearly-delineated axons of varied caliber
were readily-outlined by the osmium-stained myelin in non-transgenic animals (L–N), tissue from endstage SOD1G93A animals had an easily
recognizable reduction of large caliber myelinated axons (O–Q). Lumbar white matter in SOD1G93A endstage animals also contained numerous
vacuoles (O, P, arrows) and frequent osmium-dense deposits (O, P, arrowheads). Scale bar: 500 mm (A, B), 100 mm (C, D), 600 mm (E–J), 25 mm (K),
100 mm(L, O), 25 mm (M, N, P, Q).
doi:10.1371/journal.pone.0042614.g005
Table 2. Quantification of lateral and ventral funiculi axons in lumbar spinal cord segments of non-transgenic and endstage
transgenic SODG93A rats.
Lateral Funiculus
Total axons 0.5–2.0 mm 2.0–5.0 mm 5.0–14 mm
Non-Tg 45681 31982 11529 2079
Non-Tg 62656 43444 16782 2299
SOD1G93A 40422 30943 8411 994
SOD1G93A 39729 30315 8467 881
Ventral Funiculus
Total axons 0.5–2.0 mm 2.0–5.0 mm 5.0–14 mm
Non-Tg 14330 8764 4433 1087
Non-Tg 16500 9830 5382 1247
SOD1G93A 11532 8037 2984 489
SOD1G93A 14002 10285 3153 536
Quantification of the axonal population in the lateral and ventral columns showed an easily recognizable reduction of large caliber myelinated axons.
doi:10.1371/journal.pone.0042614.t002
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motoneurons, transient improvement in ambulatory function,
corresponding transient preservation of H-reflex activity, and
decreased inflammatory responses. Our findings add to earlier
evidence that reported i) preservation of a-motoneurons in lumbar
spinal cord in SOD1G93A rats after unilateral grafting of human
neural stem cells genetically modified to produce glial cell line-
derived neurotrophic factor (GDNF) [26] and ii) functional
improvement (as assessed by extended survival and disease
duration, improved forelimb motor and respiratory functions)
and corresponding decrease in a-motoneuron degeneration in
SOD1G93A rats receiving cervical grafts of rat astrocyte precursors
[12].
Despite initial reports 18 and 9 years ago, respectively, of
SOD1G93A mutant mouse and rat transgenic models [5,27], there
is only one characterization of the degree of upper motor neuron
degeneration in one mouse model [28] and none in the rat. To
this, our current MEPs data show that in symptomatic animals
there is a near complete loss of descending motor tract
conductivity measured directly from the dural surface of the
exposed Th12 spinal segment (Fig. 4). This functional loss
corresponds with massive axonal degeneration in the white matter
particularly affecting large caliber myelinated axons in the anterior
and lateral funiculus (Fig. 5). This is consistent with a classical
picture of spinal histopathological changes in ALS patients which,
in addition to spinal a-motoneuronal loss, is characterized by
upper motor neuron lesion and degeneration involving the entire
corticospinal tract [29–32]. Interestingly, in contrast to humans,
preferential degeneration of axons in lateral and ventral funiculus
was seen in symptomatic SOD1G93A rats while relatively spared
axonal populations were seen in the dorsal funiculus (i.e., the
region of corticospinal tract in rats). Whether or not it is the result
of species specificity is not known, however, one important
functional distinction between the organization of the different
motor systems involved in voluntary motor function exists between
human and rodents. It has been demonstrated that after complete
transection of the pyramidal tract in rats a considerable amount of
motor function persists [33]. It is believed that the activity of the
extrapyramidal system (such as rubrospinal tract which descend in
lateral funiculi in the rat) plays a more dominant role in the
initiation and maintenance of voluntary movement in rats. We
speculate that a more pronounced axonal loss seen in the lateral
funiculi in symptomatic SOD1G93A rats can thus be attributed to a
specific motor circuitry-controlling function of descending motor
axons residing in this region.
Based on these histopathological and functional data demon-
strating an extensive loss of descending motor system in
SOD1G93A rats it is readily apparent that unless the functional
integrity of all components of the motor neuraxis is maintained (or
restored) by a given treatment, only local and/or time-limited
functional protection can be achieved, just what we have produced
with hNSCs grafts.
We found no survival benefit versus our control media-injected
group, despite transient local improvement. This was not
unexpected, since for humane reasons survival in this animal
model is defined by a loss of righting reflex (i.e., the ability of the
animal to right itself). An intact righting reflex requires coordi-
nated hindlimb and forelimb motor function and continuing
functional coupling of the upper and lower motor neuron system.
In deficits which include upper and lower motor neuron
degeneration (such as seen in SOD1G93A rats), region-restricted
treatments (as achieved after spinal segmental cell grafting) is not
expected to significantly modify upper motor neuron degeneration
and loss and the associated progressive decline in righting reflex.
Nevertheless, using lumbar spinal grafting of human spinal neural
stem cells similar to those of our current study, Xu et al. (2006)
[16] previously reported an apparent lifespan extension of
Figure 6. SOD1G93A rats receiving lumbar grafts of human spinal neural stem cells showed transient protection of hindlimb motor
function and Hoffmann reflex. Population analyses of media-treated and cell-grafted animals showed no difference in: disease onset - defined as
peak body weight (A), early disease progression - defined as the age at which animals had lost 10% body weight (B), or survival (C). Hindlimb motor
function assessed by BBB neurological score (D) showed a significantly better score in hNSCs-grafted animals between ages 135–142 d. Similarly,
Hoffman reflex recorded in cell-grafted animals during that time period had significantly higher average amplitudes than those from the media-
treated group (E), (* P,0.05).
doi:10.1371/journal.pone.0042614.g006
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SOD1G93A rats of 11 days (average 149 days) compared to control
animals receiving injection of dead cells (average 138 days).
Similar to our study a significantly higher number of persisting
lumbar a-motoneurons was found in treated animals. More
recently, Xu et al. (2011) reported a lifespan extension of
SOD1G93A rats by 17 days after dual cervical (C4–C5) and
lumbar (L4–L5) transplantation of the same human spinal neural
stem cell line as used in our current study [34]. Given the robust
graft survival, cell differentiation and migration seen in our study,
we speculate that the differences between ours and these prior
studies may reflect the occurrence of natural drift in the onset of
disease between different cohorts of animals (a feature that has
been argued to necessitate .25 animals per group in order to
draw statistically valid conclusions) [35] and/or difference in the
design of the control groups (i.e., injections of dead cells vs. media
only) and potentiation of local neuronal degeneration in dead cell-
injected animals.
Several differential characteristics between rodent models and
human ALS patients need to be considered when predicting the
potential value of spinal cell replacement therapies in human
patients. First is a significantly different time course of disease
progression in rodents and human patients. In SOD1G93A rodent
models the average duration of disease from the initiation of
denervation-induced weight loss to terminal stage is 60–70 days in
mice [5,27,36,37] and is around 27 days in rat [38]. In human
ALS patients it can range between months to several years [1,32].
Such differences have a fundamental impact on the degree of
engraftment, maturation and migration of grafted cells, and can
ultimately define the degree of expected neuroprotection. In our
current experimental design, SOD1G93A rats were implanted at
age,65 days (i.e., on average,44 days prior to disease onset) and
had an average survival time of 75 days after cell grafting (an
average of ,140 days to endstage). While robust neuronal
differentiation was noted in grafted animals, only limited cell
migration was seen in the short term to areas distant from cell-
injected regions. Cell migration at 9 months post-grafting in naive,
immunodeficient rats, a time period comparable to that expected
in human patients receiving spinal grafts, was determined. In
contrast to short times post-grafting, much more robust cell
migration was seen, with a homogenous distribution of grafted
cells identified in white and gray matter (Fig. 3). Cells found in
white matter showed near-exclusive differentiation towards
astrocytes and oligodendrocytes. These findings support the
likelihood that comparable spinal cell repopulation can be
expected in human patients postgrafting and that this can be
associated with a more relevant functional-protective effect.
Combined cell grafting strategies targeted in parallel to spinal
and supraspinal motor centers can be anticipated, therefore, to
provide a substantial degree of neuroprotection measured both
behaviorally as well as by using combined motor and somatosen-
sory-evoked recording.
A second important component in achieving optimal therapeu-
tic benefit in cell replacement therapies is the selection of cell lines
(e.g., neural, neuronal or glial-restricted) to be used for spinal/
supraspinal grafting. The primary selection criteria should reflect
the disease stage and targeted cell population to be replaced, that
is, cells whose damage drives early or late disease phases. Since one
of the well documented mechanisms contributing to disease
progression is the release of toxic factors from SOD1 mutant
astrocytes and resultant neuronal degeneration [8,9,11,39], the use
of wild type astrocyte precursors for grafting may appear to be an
attractive choice. Data from the Maragakis’ group [12] demon-
strated a region specific therapeutic effect when cells were grafted
into the cervical gray matter in presymptomatic SOD1G93A rats.
However, the absolute number of spinal (and also brain)
astrocytes may not be static and there is a continued proliferation
of glial precursors in the intact adult CNS [40]. In addition, there
is increased astrocyte proliferation after injury such as spinal
trauma or focal brain ischemia [41,42]. More recent studies using
in vivo BrdU incorporation assay have shown that, while the
primary cellular contribution to spinal cord gliosis seen in
symptomatic and endstage SOD1mutant (G93A) mice is derived
from oligodendrocyte-committed NG2+ precursors (up to 49–
55%), between 4–5% of BrdU-labeled cells are GFAP-immuno-
reactive astrocytes [43,44]. These data show modest but continu-
ing proliferation of mutated SOD1 astrocytes throughout the
disease progression. Thus, there may be a competitive interaction
between replication of the host mutated astrocytes and grafted
wild-type astrocyte precursors.
Moreover, from a clinical perspective, one of the limitations in
using a lineage restricted precursor population is the potential that
it may be targeted for damage and potentially replaced by
endogenous mutant astrocyte population. In experimental rodent
studies, cells are typically grafted at pre-symptomatic stages while
the clinical patient population will primarily be composed of
symptomatic patients, with existing upper and/or lower moto-
neuron/interneuron degeneration. Because there is no evidence of
neurogenesis in adult naive or trauma injured spinal cord [40,45],
the primary goal in cell replacement therapies that employ glial-
restricted precursors will therefore be to stabilize or slow neural
degeneration. Second, given the large number of astrocytes
compared to neurons in the adult CNS, there is a limited
likelihood of achieving significant astrocyte repopulation using
cells lines with little or no mitotic/migratory activity, so an
important characteristic of astrocyte-restricted lines for grafting is
their continuing proliferative/migratory capacity after transplan-
tation. Our current data using 9 month surviving cell-grafted
immunodeficient rats demonstrate widespread grafted cell migra-
tion with no detectable tumor formation. More recently, we have
observed comparable cell migration and safety of human
embryonic stem cell (H9)-derived neural stem cells at 5–6 months
after spinal grafting in immunodeficient rats (unpublished obser-
vations). Nonetheless, a detailed long-term safety/tumorigenicity
profile will need to be established for each individual cell line
before clinical use.
Finally, our evidence highlights that the use of human fetal
spinal cord-derived neural stem cells which can generate astrocytes
but mostly neurons in vivo have a limited, local therapeutic effect.
Therefore, an optimal cell line will likely produce a mixture of glial
and neuronal stem cells having both proliferative (at least for the
astrocyte-restricted subpopulation) and migratory properties. As
demonstrated in our current study, human fetal spinal cord-
derived neural stem cells have such properties to a certain extent,
albeit a higher ratio of astrocyte precursors in the grafted cell
population might be preferable. It now remains to be determined
whether human embryonic stem cells-derived neural stem cells will
show a distinct differentiation ratio and more rapid migration in
an ALS environment after in vivo grafting in humans.
In any event, cell replacement therapies should target both
spinal and supraspinal components of motor neuraxis. Because the
multi-site delivery of therapeutic cells is clearly technically more
challenging, additional safety data as well as the development of
less invasive cell delivery techniques will be required before this
potentially more effective multi-site cell delivery treatment
approach can successfully be introduced into clinical practice.
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Methods
Ethics Statement and Institutional Animal Care and Use
Committee approvals
This study was approved by the University of California, San
Diego (UCSD) Internal Review Board (IRB), approval
ID#101323.
All animal studies were carried out under protocols approved by
the Institutional Animal Care and Use Committee at University of
California (approval Ids # S01193 and S07016) San Diego and
were in compliance with The Association for Assessment of Laboratory
Animal Care guidelines for animal use. All studies were performed in
such a manner as to minimize group size and animal suffering.
Derivation of the human fetal spinal neural stem cells
(hNSCs)
Human fetal spinal neural stem cells (hNSCs) were prepared
from the cervical–upper thoracic region of spinal cord tissue
obtained from a single 8-week human fetus after an elective
abortion. The fetal tissue was donated by the mother in a manner
fully compliant with the guidelines of NIH and FDA and approved
by an outside independent review board. The spinal cord tissue
was removed of meninges and dorsal root ganglia and dissociated
into a single cell suspension by mechanical trituration in serum-
free, modified N2 media. The modified N2 media was composed
of: 100 mg/l human plasma apo-transferrin, 25 mg/l recombi-
nant human insulin, 1.56 g/l glucose, 20 nM progesterone,
100 mM putrescine, and 30 nM sodium selenite in DMEM/F12.
For growth of the hNSCs, 10 ng/ml bFGF as the sole mitogen was
added to the modified N2 media (growth media). The initial
culture was serially expanded as a monolayer culture in precoated
flasks (T-175) or plates [46]. Briefly, the precoated vessels were
prepared by incubating them for 1 h at room temperature with
100 mg/ml poly-D-lysine in 10 mM Hepes buffer at 0.165 ml/
cm2. The vessels were washed three times with water and allowed
to completely dry aseptically in the hood. They were then further
incubated with 100 mg/ml fibronectin/PBS for 5 min or alterna-
tively 25 mg/ml fibronectin/PBS for 1 h. The fibronectin solution
was aspirated and the vessels were used immediately without
drying. Approximately 6.16106 total cells were obtained upon the
initial dissociation of the spinal cord tissue. All of the cells were
plated onto one 150 mm plate in 20 ml of the growth media.
The growth medium was changed every other day and in the
alternate days, 10 ng/ml of bFGF was directly added to the
culture. The first passage was conducted 16 days after plating. At
this point, the culture was composed mostly of post-mitotic
neurons and mitotic hNSCs. The mitotic cells were harvested by
brief treatment with trypsin (0.05% in 0.53 mM EDTA). Trypsin
was stopped by addition of soybean trypsin inhibitor to 0.05%
final concentration. The cell suspension was triturated with a
pipette to obtain a single cell suspension and centrifuged at
1400 rpm for 5 min. The cell pellet was resuspended in growth
media and the cells were replated in new pre-coated plates at
1.26106 cells in 20 ml of growth media per 150 mm plate. The
cells were harvested at approximately 75% confluence, which
occurred in 5–6 days. This process was repeated for 20 passages.
At various passages, the cells were frozen in the growth medium
plus 10% DMSO at 56106–106106 cells/ml using a program-
mable freezer. The frozen cells were stored in liquid nitrogen.
Upon thawing, the overall viability and recovery was typically 80–
95%. The resulting cell line, which was produced by epigenetic
means only, using bFGF as the sole mitogen, was named
‘‘566RSC.’’ A cell bank of passage 16 cells was prepared and
used for this study.
Preparation of hNSCs for implantation
One day prior to each surgery day, one cryopreserved vial of the
previously prepared passage 16 cell bank was thawed, washed,
concentrated in a hibernation buffer, and shipped from the cell
preparation site (Neuralstem, Inc., Rockville, MD, USA) to the
surgery site (UCSD, San Diego, CA, USA) at 2–8uC by overnight
delivery. Upon receipt the following day, the cells were used
directly for implantation without further manipulation. Before and
after implantation the viability of cells was measured with Trypan
blue (0.4%; Sigma). On average a 75–85% viability rate was
recorded.
Experimental groups
Before cell grafting, SOD1G93A transgenic rats were randomly
divided into 3 experimental groups – no treatment (untreated
SOD1G93A), media-treated SOD1G93A, and cell-grafted
SOD1G93A; non-transgenic littermates were used as control
animals and received no treatment. A total of 24 animals (12
males, 12 females) were assigned to the cell-grafted SOD1G93A
group, while 16 animals (8 males, 8 females) were assigned to
receive media only. Immunosuppressive treatment with Prograf
(FK506; 3 mg/kg/day subcutaneous; Astellas Pharma, Deerfield,
IL) and Cellcept (mycophenolate mofetil; 30 mg/kg/day intra-
peritoneal; Roche Pharmaceuticals, Nutley NJ) were initiated 2 d
before transplantation. Cellcept continued to 7 d post-surgery,
while Prograf was changed to 1 mg/kg/day at 14 d post-op and
continued until the study end. A separate group of athymic rats
(Crl:NIH-Foxn1rnu; n = 12; Charles River) was used for a subset of
experiments but underwent no immunosuppression.
Motor-evoked potentials were recorded from the dorsal surface
of the lumbar spinal cord (see Motor-evoked potentials recording)
in a separate group of endstage SOD1G93A animals (n = 6) and
non-transgenic controls (n = 6) which did not undergo any
treatment or spinal injections. The same animals were then used
for qualitative and quantitative analysis of axonal degeneration/
loss of spinal descending motor tracts using silver impregnation
techniques and plastic-embedded semithin sections (see Plastic
embedding and Silver degeneration staining).
Spinal cord implantation of hNSCs
Animals (60–65 d old) were anesthetized with isoflurane (1.5–
2% maintenance; in room air), placed into a spinal clamp
apparatus (Stoelting, Wood Dale, IL, USA) and a partial T12–L1
laminectomy was performed using a dental drill (exposing the
dorsal surface of L2–L6 segments). Using a glass capillary (tip
diameter 80–100 mm) connected to a microinjector (Kopf
Instruments, Tujunga, CA), rats were injected with 0.5 ml
(10,000 cells per injection) of the hNSCs in hibernation buffer,
or only the hibernation buffer as control (media). The duration of
each injection was 60 s followed by 30 s pause before capillary
withdrawal. The center of the injection was targeted into the
intermediate zone and ventral horn (distance from the dorsal
surface of the spinal cord at L3 level: 1.1–1.2 mm), [47]. Injections
were made every 700–900 mm, rostro-caudally, on each side of the
lumbar spinal cord targeting L2–L5 segments. The total number
of injections ranged between 9–13 injections per side. After
injections, the incision was cleaned with penicillin-streptomycin
solution and sutured in two layers. Athymic rats were transplanted
in an identical fashion.
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Assessment of neurological function and disease
progression
Motor function was evaluated using the 21-point open field BBB
locomotor scale [48]. Animals were observed for 4–5 min and
scored by an experimenter blinded to the treatment groups. Disease
onset was defined as the age of maximum body weight; Early disease
was defined as the point at which the animal lost 10% of peak
body weight; Endstage was defined as when an animal could not
right itself after 30 s of being placed on its side [38].
Hoffman reflex (H-reflex) recording
H-reflex was recorded as previously described [49,50]. Under
ketamine anesthesia (100 mg/kg/hr, i.m.) the right hind limb of
the animal was secured and a pair of stimulating needle electrodes
was transcutaneously inserted into the surroundings of the tibial
nerve. For recording a pair of silver needle electrodes was placed
into the interosseous muscles between the fourth and the fifth or
the first and the second metatarsal right foot muscles. The tibial
nerve was stimulated using square pulses with increasing stimulus
intensity (0.1–10 mA in 0.5 mA increments, 0.1 Hz, 0.2 ms; WPI;
Isostim A320) and responses were recorded with an A/C-coupled
differential amplifier (Model DB4; DPI, Sarasota, FL).
Motor-evoked potential recording
Under isoflurane anesthesia (1.5–2% maintenance; in room air),
terminal SOD1G93A rats (n = 6 or age-matched controls, n = 6)
without any previous treatment (i.e., no spinal injections) were
mounted into a stereotaxic frame and the scalp over motor cortex
was cut open to expose the skull. Stimulation was done using a pair
of stimulating electrodes consisting of a stainless steel screw placed
into the skull over the motor cortex and stainless steel needle
inserted into the hard palate behind the upper incisors. Previous
data show that such placement of stimulating electrodes provides
consistent activation of pyramidal and extrapyramidal system (19–
21).
A dental drill was used to perform a laminectomy of T11
vertebra exposing the T12 spinal segment. Evoked responses were
recorded by a pair of flexible silver ball electrodes placed on the
dura surface of the exposed T12 spinal segment. A reference silver-
chloride disc electrode was placed subcutaneously on the
contralateral side of the recording. After electrode placement,
animals were injected with ketamine (100 mg/kg/h, I.M.) and
isoflurane anesthesia was discontinued. Stimulation pulses were
0.2 ms long with amplitudes ranging from 0.5 to 8 mA (Isostim
A320R, World Precision Instruments, Florida, USA). Signals from
recording electrodes were filtered by 10 kHz low pass filter,
amplified by differential amplifier (TDT DB4 amplifier with HS4
preamplifier, Tucker-Davis Technologies, Florida, USA), digitized
in 30 kHz sampling frequency and stored for further analysis.
Immunohistochemistry
At endstage disease, rats were deeply anesthetized with
pentobarbital and phenytoin and transcardially perfused with
200 ml of heparinized saline followed by 250 ml of 4%
paraformaldehyde in PBS. The spinal cords were dissected and
postfixed in 4% formaldehyde in PBS overnight at 4uC and then
cryoprotected in 30% sucrose PBS until transverse sections (30 mm
thick) were cut on a cryostat and stored in PBS. Sections for
brightfield immunohistochemical staining were pretreated with
3% H2O2 in PBS for 15 min, washed 36 in PBS and were then
placed in primary antibody similar as sections for fluorescent
staining: overnight at 4uC with primary human specific (h) or non-
specific antibodies made in PBS with 0.2% Triton-X100: mouse
anti-human nuclear matrix protein/h-nuc (hNUMA; 1:100;
Millipore, Temecula, CA, USA); goat anti-doublecortin (DCX;
1:1000; Millipore, Temecula, CA); mouse anti-human neuron
specific enolase (hNSE; 1:200, Vector Laboratories Inc., Burlin-
game, CA); rabbit anti-glial fabrillary acidic protein (GFAP,
1:1000, Sigma-Aldrich Corp. St. Louis, MO); goat anti-choline
acetyltransferase (ChAT; 1:100; Millipore, Temecula, CA);
biotinylated mouse anti-NeuN (Millipore, Temecula, CA); mouse
anti-adenomatus polyposis coli (APC; 1:500; EMD Chemicals
Inc., Gibbstown, NJ); chicken anti-beta III tubulin (TUJ1; 1:1000;
Aves Labs Inc, Tigard, OR); rabbit anti-ionized calcium binding
adaptor molecule 1 (Iba1; 1:1000; Wako Chemicals USA, Inc.,
Richmond, VA); mouse anti-human synaptophysin (hSYN;
1:1000; Millipore, Temecula, CA); guinea pig anti-vesicular
glutamate transporter (VGluT1- 1:2500; VGluT2 – 1:2500;
VGluT3 – 1:5000; Millipore, Temecula, CA); guinea pig anti-
glycine transporter 2 (GlyT2; 1:2000; Millipore, Temecula, CA);
rabbit anti-growth associated protein 43 (GAP43; 1:500; Millipore,
Temecula, CA); rabbit anti-glutamate decarboxylase 65 (GAD65;
1:2000; Millipore, Temecula, CA).
After incubation with primary antibodies, sections were washed
36 in PBS and incubated with fluorescent-conjugated secondary
antibodies raised in donkey (Alexa 488, 546; 647; 1:250;
Invitrogen Corp., Carlsbad, CA, USA) and DAPI for general
nuclear staining. In cases where 2 mouse antibodies were required
for multi-labeling, one was biotinylated using a Zenon mouse IgG
labeling kit according to the manufacturer’s instructions (Invitro-
gen Corp., Carlsbad, CA, USA). Once staining was complete,
sections were mounted on slides, dried at room temperature and
covered with Prolong anti-fade kit (Invitrogen Corp., Carlsbad,
CA, USA). Sections for brightfield were washed after primary
antibody, placed in biotinylated secondary antibody (goat anti-
mouse; 1:500; Vector Laboratories, Burlingame, CA) for 2 h at
room temperature. Those sections were again washed, placed in
avidin-biotin complex (ABC kit, Vector Laboratories, Burlingame,
CA) for 2 h at room temperature. Finally, the sections were
washed, developed with 3,39-diaminobenzidine (DAB; Vector
Laboratories, Burlingame, CA), mounted on silane-coated slides,
air-dried, dehydrated and coverslipped. Images were captured
using a Leica DMLB microscope with a Zeiss Axiocam MRm
monochrome camera. Some images were captured using a Leica
SP2 confocal microscope. Any image post-processing was done
with Adobe CS3 (Adobe Systems, Inc., San Jose, CA) with equal
changes to any images being compared.
Plastic embedding
For plastic embedding, spinal cord blocks (2–3 mm thick) were
postfixed in 0.3% glutaraldehyde for 1 day at 4uC. Tissue was
rinsed 365 min in 0.1 M phosphate buffer (pH 7.4), and stored in
phosphate buffer overnight at 4uC. Secondary postfixation was
performed using 0.1% osmium tetroxide in 0.1 M phosphate
buffer for 12 hours, followed by rinsing in phosphate buffer. This
was followed by progressive alcohol dehydration according to
standard procedures up to 100% ethanol, with the addition of
further dehydration in a 1:1 solution of ethanol/propylene oxide,
and lastly 100% propylene oxide. Dehydrated blocks were then
prepared for resin infiltration by incubation in a 1:1 solution of
resin/propylene oxide overnight. The resin included: Eponate 12,
Araldite 502, Dodecenyl Succinic Anhydride (DDSA), and 2,4,6-
Tri[Dimethylaminomethyl]phenol (DMP-30) (Ted Pella Inc),
mixed in ratios of 10:10:25:1 respectively. Blocks were then
transferred to 100% resin for subsequent overnight infiltration on
a rotator. Finally, tissue blocks were embedded using fresh resin in
multi-chamber silicone rubber molds (Ted Pella). The mold was
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placed in an oven (60uC) for 2 days to facilitate resin
polymerization. Semithin (1 mm) transverse sections were then
cut using a Leica (DM-40) microtome with glass knives. Sections
were mounted to slides from distilled water and allowed to dry on
slide warmer. Prior to staining, slides were incubated at 60uC in an
oven for 10–15 minutes, and then contrast-stained with 4% para-
phenylenediamine (PPD).
Silver degeneration staining
De Olmos aminocupric silver impregnation. Neurode-
generation was assessed using the de Olmos aminocupric silver
histochemical technique as previously described [23,25]. Following
the vendor’s instructions (Neuroscience Associates, TN, USA),
SOD1G93A endstage rats and non-transgenic age-matched litter-
mates were transcardially perfused with cacodylate-modified PBS
followed by cacodylate-modified paraformaldehyde and brain and
spinal cord tissue shipped to Neuroscience Associates for processing.
Gallyas silver impregnation [22]. Paraformaldehyde-fixed
spinal cord tissue was embedded in paraffin wax and 12 mm thick
sections were cut and mounted directly on slide. After dewaxing in
xylene and progressive rehydration to water, the slides were placed
in fresh 0.3% magnesium permanganate and subsequently rinsed
in tap water for 10 minutes. Further magnesium permanganate
clearing was done in 2% oxalic acid for 3 min. Background
suppression was facilitated by incubation in fresh 0.004%
lanthanum nitrate/0.02% sodium acetate solution for 60 minutes.
Following wash, slides were placed into a silver iodide solution for
2 minutes, and then neutralized by three washes in 0.5% acetic
acid. The intensity of silver impregnated structures was amplified
with by immersion in a 1:1 ratio of two physical developer
solutions: A: ammonium nitrate, silver nitrate, tungstosilic acid,
and formaldehyde; and B: 5% anhydrous sodium carbonate
solution. Slides were then quickly washed in 0.5% acetic acid, and
placed into a 0.5% gold chloride solution for 5–10 minutes. Slides
were rinsed in distilled water, placed in 2% sodium sulfate
(2 minutes) and rewashed in distilled water before they were
progressively dehydrated to xylene and cover slipped in DPX.
Immuno-electron microscopy
Transverse spinal cord sections (50 mm thick) were prepared
from lumbar spinal cords of immunodeficient rats at 9 months
after hNSCs grafting. Sections were cut on a vibratome and
cryoprotected with glycerol–dimethylsulfoxide mixture. After
cryoprotection, the sections were frozen and thawed four times
and treated with 1% sodium borohydrate. To reduce nonspecific
binding, the sections were treated with 0.3% H2O2–10%
methanol in TBS (100 mM Tris-HCl and 150 mM NaCl,
pH 7.6) and 3% NGS–1% bovine serum albumin in TBS.
Sections were reacted overnight with mouse anti-human-specific
synaptophysin (1:1000; Chemicon). Bound antibody was detected
using biotinylated donkey anti-mouse IgG (1:500; GE Healthcare,
Little Chalfont, UK), the ABC Elite kit (Vector Laboratories,
Burlingame, CA), and diaminobenzidine (DAB) as the chromogen.
After DAB detection, some sections were processed by an
additional antibody labeling cycle using the same method and
antibody as above. This staining strategy enhanced the signal-to-
background ratio while the background labeling was kept to
minimal. Immunoreacted sections were postfixed in buffered 2%
OsO4, rinsed and stained in 1% uranyl acetate, and then
dehydrated and embedded in Epon. Ultrathin sections were
contrasted with uranyl acetate and analyzed under a Zeiss EM-10
electron microscope operated at 60–80 kV. Electron microscopic
negatives were scanned and processed by Adobe Photoshop CS2
(Adobe Systems).
Quantitative immunohistochemistry
GFAP/Iba1 densitometry. Immunohistochemical staining
was performed using the same antibody solution for all free-
floating sections and processed as described above. Randomly
selected four sections (from L4 and L5 spinal cord segments) were
analyzed from each animal. Using identical camera settings,
images were obtained from lamina IX on both sides of each
section. Using the pixel histogram generated for each original
image by Image-Pro Plus (v.6.2.0.424; Media Cybernetics Inc.,
Bethesda, MD), the product of the pixel number and pixel
intensity value (0–255) was computed and summed for the entire
image. This provides a composite measure of changes in both
immunoreactive area and intensity.
Neuronal bouton analyses. Bouton analyses were per-
formed as previously described, [51–54]. The investigator was
blinded during analyses. Using immunofluorescence-stained sec-
tions and identical microscope settings, 3 images (75 mm675 mm)
were captured from lamina IX (adjacent to a CHAT+ a-
motoneuron surrounded by hSYN staining) of each section using
a Leica SP2 confocal microscope; at least 3 sections (300 mm
separation) were used from each of 5 animals. Image-Pro Plus
(v.6.2.0.424; Media Cybernetics Inc., Bethesda, MD) was used to
count the total number of human synaptophysin-immunoreactive
objects using the same limits for pixel intensity and structure size.
The image was then overlaid onto another image from the
identical field but stained for other neuronal phenotype markers
(VGluT1/2/3, GAD65, GlyT2). The total number of double-
positive structures was then identified by Image-Pro Plus. The
number of hSYN+ punctata identified on each a-motoneuron
ranged between 30–80 per a-motoneuron.
a-motoneuron quantification. Alpha-motoneuron quantifi-
cation was performed as previously described [55] except using
fluorescent-stained (ChAT) tissue sections. The investigator was
blinded during all analyses. Five sections taken from C5–C6 or
L4–L5 segments, each separated by minimum of 300 mm, were
selected from each animal (n = 18 for the cell-grafted group and
n = 16 for the media-injected group; i.e., a total of 90 and 80
sections, respectively) and were identically immunostained for
ChAT. Sections from grafted animals had graft presence
confirmed by additional hNUMA staining. A single 206 image
was then captured (focused in the center of the section thickness)
from each lamina IX and analyzed with Image-Pro Plus
(v.6.2.0.424; Media Cybernetics Inc., Bethesda, MD) to determine
CHAT+ a-motoneurons with surface area .700 mm and a
staining intensity that was at least 2-fold over background (same
threshold used for all a-motoneuron analyses) [56]. Cells identified
by Image-Pro Plus were then examined and those with distinct
nucleoli, as defined by clearly detectable lack of CHAT
immunoreactivity in the nucleoli, were counted (see Fig. S 4C
for details).
Graft phenotype characterization (NeuN, GFAP, APC,
DCX). To determine the phenotype of the grafted human cells,
tissue sections from the L4–L5 engrafted region were double-
stained with hNUMA and either NeuN, GFAP, APC, or DCX, as
described above. Using identical microscope settings, a z-stack of
optical images (0.5-mm-thick; 206 objective) were captured from
identified hNUMA+ grafts using a Leica SP2 confocal microscope;
at least 3 sections (300 mm separation) were used from each of the
5 animals. Image-Pro Plus (v.6.2.0.424; Media Cybernetics Inc.,
Bethesda, MD) was then used to identify positive cells in one
overlaid optical image (0.5-mm-thick) using identical thresholds for
all images. All images were examined by a blinded observer.
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Axonal Quantification
The total number of remaining axons was determined in the
lateral and ventral funiculi using semi-automated image analysis of
osmium-treated 1-mm plastic sections taken from the lumbar spinal
cord of normal (n = 2) and SOD1G93A (n = 2) endstage animals
with no previous manipulations (i.e., no spinal media or cell
injections).
High resolution mosaic images were obtained using Zeiss
Observer software with Multidimensional Acquisition MosiaX (Z1
microscope system with 206 objective fitted with a Zeiss MRm
camera, AxioVision v4.7). Using the same pixel threshold to
identify axons in all images, Image-Pro Plus (v.6.2.0.424; Media
Cybernetics Inc., Bethesda, MD) was used to objectively count
axons. Further measurement parameters such as area/box and
size (length) were applied to discriminate and exclude non-axonal
objects. Employment of the size (length) parameter allowed for
further axonal analysis in which axons were divided into
empirically derived caliber sizes of small, medium, and large
axons (0.5–2.0 mm, 2.01–5.0 mm, and 5.01–14.0 mm respectively).
Statistical analysis
Two-way comparisons were performed by student t-test.
Multiple comparisons were performed using one-way analysis of
variance (ANOVA) followed by Student-Newman-Keuls test. All
results are shown as mean 6 standard error of mean (SEM) unless
indicated. P,0.05 was considered to be statistically significant.
Supporting Information
Figure S1 Grafted human spinal neural stem cells show
expression of several neuronal markers. Histological
sections taken from regions containing human spinal neural stem
cell transplants were immunostained with neuronal cells markers
TUJ1, DCX and GAP43. Human cells were identified by the
presence of human-specific nuclear matrix antigen (hNUMA), (A,
D). Cell grafts were typically concentrated in the deeper lamina
(VII–IX) and frequently extended into the adjacent white matter.
Regions stained for hNUMA were also strongly stained for beta-
tubulin III (TUJ1; B), doublecortin (DCX; E), and growth-
associated protein 43 (GAP43; F). Scale bar (G) is 300 mm for all
panels.
(TIF)
Figure S2 Grafted, terminally differentiated human
neural spinal stem cells-derived neurons develop puta-
tive synaptic contact with persisting a-motoneurons in
SOD1G93A rats. Human synaptophysin (hSYN) was detected
throughout the cell grafts, often found in axonal-like structures
with typical varicosities (B insert) and in the vicinity of persisting a-
motoneurons (ChAT; choline acetyltranseferase) in lamina IX and
extending into the adjacent white matter (A–D). Single optical
layer confocal images of surviving a -motoneurons show hSYN-IR
bouton-like structures adjacent to the outer membrane of the soma
(E, F), occasionally expressing the GABAergic cell marker
glutamate decarboxylase (GAD65), (G, H). Human glutamatergic
boutons were located by identifying specific glutamate vesicular
transporters 1/2/3 (VGluT) and similarly showed only rare
boutons also reactive for hSYN (I–L). Glycinergic boutons were
identified by the neuronal-specific glycine transporter 2 (GlyT2),
(M–P). Arrows show examples of double-immunoreactive struc-
tures. Scale bar: 300 mm (A–D), 25 mm (E–P).
(TIF)
Figure S3 Spinal grafts of human spinal neural stem
cells reduced astrogliosis and microglial activation in
SOD1G93A rats. Quantitative densitometry was performed on
lumbar (L4 and L5) spinal cord sections immunostained for
astrocytes (GFAP) and microglia (Iba1). Lamina IX images were
captured from non-transgenic (A–C), untreated SOD1G93A (D–F),
media-treated SOD1G93A (G–I), and cell-grafted SOD1G93A (J–L)
animals. All three SOD1G93A groups show signs of strong
astrogliosis and microglia infiltration/activation, with a marked
increase in the number of GFAP-IR hypertrophic astrocytes and
dense Iba1-immunoreactivity (IR). Based on densitometric
analyses, lamina IX GFAP-IR and Iba1-IR in SOD1G93A and
media-treated groups were significantly increased over the non-
transgenic group (M). Reduced GFAP-IR and Iba1-IR was
measured in the cell-grafted group (M). Scale bar: 80 mm. (*
significantly increased over non-transgenic; P,0.05; one-way
ANOVA); ** significantly increased over non-transgenic but
decreased from media-treated; P,0.05; one-way ANOVA).
(TIF)
Figure S4 Migration of grafted human fetal spinal
neural stem cells in lumbar spinal cord in SOD1G93A
rats at 78 days after grafting or in immunodeficient rats
at 9 months after grafting. By comparing the spread of
hNUMA+ cells in SOD1G93A rats at 78 days after grafting (A) with
that seen in immunodeficient rats at 9 months (B), wide spread of
grafted cells in both the gray matter and white matter was seen at
9 months (A, B; compare red asterisks in the dorsal and lateral
funiculi). To quantify a-motoneurons, CHAT immunofluores-
cence-stained sections were used. Cells to be counted were
identified by surface area (.700 mm) and by the presence of
nucleoli as evidenced by an easily identifiable lack of CHAT
staining in the center of nucleus (C; red arrows).
(TIF)
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